Welcome to our four-part series Biosimilars: Addressing the Knowledge Gaps, hosted by Dr. Christina Ha. Each episode features a challenging patient case and short discussion.
In episode 2 of 4, we’re joined by guest Frank I. Scott, MD to discuss:
- How do you prepare your team and the patient for a switch to a biosimilar?
- Are there any situations where switching is not appropriate?
- What do you think about multiple switches?
- How do you minimize the potential for a nocebo effect?
Faculty
Christina Y. Ha, MD, AGAF
Miguel D. Regueiro, MD, AGAF
Jennifer Seminerio-Diehl, MD
Frank I Scott, MD
Shubha Bhat, PharmD, MS
Learning Objectives:
- Summarize key efficacy, safety and similarity evidence from clinical studies and real-world experience related to biosimilar products
- Explain the lack of clinically meaningful differences between an FDA-approved biosimilar and the originator biologic
- Implement effective strategies for discussing biosimilar options in a shared decision-making process
- Demonstrate increased familiarity and confidence in the use of biosimilar products
Disclosures
Christina Y. Ha, MD, AGAF
- Consulting: AbbVie, Janssen, Pfizer, Takeda, Bristol Myers Squibb, InDex Pharmaceuticals, Genentech
- Education Support: Pfizer
Miguel D. Regueiro, MD, AGAF
- Consulting: Abbvie, Janssen, Pfizer, BMS, Lilly, Organon
Jennifer Seminerio-Diehl, MD
- Consulting: Abbvie, Pfizer, Janssen, Takeda, BMS
Shubha Bhat, PharmD, MS
- Consulting: BMS, Prometheus Laboratories, Pfizer, Pharmacomos, Boehringer Ingelheim
Frank I Scott, MD
- Consulting:
Takeda Pharmaceuticals, Janssen Pharmaceuticals, IBD Remedy
Planning committee
Monique Dyson, MS, CHES
Maura Davis
Lynn Nye
Jeri McMacken
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Jan. 1, 2024